# US 2001/0024638 A1 · Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024638 A1
- Document ID: US20010024638A1
- Status: Published application
- Kind: A1
- Application number: 09/770,216
- Filed: 2001-01-29
- Published: 2001-09-27
- Earliest claimed: 1992-11-02
- Inventors: Michel Schneider; Jean Brochot; Jerome Puginier; Feng Yan
- Web page: https://patentgrep.com/patent/US20010024638A1

## CPC

- A61K 49/223: {Microbubbles, hollow microspheres, free gas bubbles, gas microspheres}
- A61K 49/225: {Microparticles, microcapsules (gas-filled to be classified in A61K49/223)}
- B62D 25/147: {with adjustable connection to the A-pillars}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B62D: MOTOR VEHICLES; TRAILERS (steering, or guiding on a desired track, of agricultural machines or implements A01B69/00; wheels, castors, axles, increasing wheel adhesion B60B; vehicle tyres, tyre inflation or tyre changing B60C; connections between vehicles of a train or the like B60D; vehicles for use on rail and road, amphibious or convertible vehicles B60F; suspension arrangements B60G; heating, cooling, ventilating or other air treating devices B60H; windows, windscreens, non-fixed roofs, doors or similar devices, protective coverings for vehicles not in use B60J; propulsion plant arrangements, auxiliary drives, transmissions, controls, instrumentation or dashboards B60K; electric equipment or propulsion of electrically-propelled vehicles B60L; power supply for electrically-propelled vehicles B60M; passenger accommodation not otherwise provided for B60N; adaptations for load transportation or to carry special loads or objects B60P; arrangement of signalling or lighting devices, the mounting or supporting thereof or circuits therefor, for vehicles in general B60Q; vehicles, vehicle fittings or vehicle parts not otherwise provided for B60R; servicing, cleaning, repairing, supporting, lifting, or manoeuvring, not otherwise provided for, B60S; brake arrangements, brake control systems or parts thereof B60T; air-cushion vehicles B60V; motor-cycles, accessories therefor B62J, B62K; testing of vehicles G01M)

## Abstract

Disclosed are injectable suspensions of gas filled microbubbles in an aqueous carrier liquid usable as contrast agents in ultrasonic echography. The suspensions comprise amphipathic compounds of which at least one may be a laminarized phospholipid as a stabiliser of the microbubbles against collapse with time and pressure. The concentration of phospholipids in the carrier liquid is below 0.01% wt but is at least equal to or above that at which phospholipid molecules are present solely at the gas microbubble-liquid interface. Also disclosed are methods of preparation of the stable suspensions of gas filled microbubbles, as well as dry formulations which, upon reconstitution in an aqueous carrier liquid, will form the injectable suspensions of gas filled microbubbles of the invention and methods of making and using the same The preferred dry formulations are stable when stored over time and at temperatures above ambient temperature and further comprise a lipid acid preserving agent additive.

## Claims

### Claim 1

An ultrasound contrast agent comprising an aqueous suspension of gas filled microbubbles comprising a saturated phospholipid, a fatty acid, a hydrophilic stabilizer, and SF6, wherein the amount of the saturated phospholipid in the suspension is less than about 0.01% by weight.

### Claim 2 (depends on 1)

The ultrasound contrast agent of claim 1, wherein the fatty acid is present in an amount between 1% and 50% by weight of the amount of the saturated phospholipid.

### Claim 3 (depends on 1)

The ultrasound contrast agent of claim 1, wherein the fatty acid is present in an amount between 5% and 25% by weight of the amount of the saturated phospholipid.

### Claim 4 (depends on 1)

The ultrasound contrast agent of claim 1, wherein the fatty acid is present in an amount between 10% and 15% by weight of the amount of the saturated phospholipid.

### Claim 5 (depends on 1)

The ultrasound contrast agent of claim 1, wherein the fatty acid is a C12-C24 straight chain saturated fatty acid selected from the group consisting of lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid and mixtures thereof.

### Claim 6 (depends on 1)

The ultrasound contrast agent of claim 1, wherein the fatty acid comprises palmitic acid in an amount between 10% and 15% by weight of the amount of the saturated phospholipid.

### Claim 7 (depends on 1)

The ultrasound contrast agent of claim 1, wherein the saturated phospholipid is selected from the group consisting of dimyristoylphosphatidic acid, dimyristoylphosphatidylglycerol, dimyristoylphosphatidylserine, dipalmitoylphosphatidic acid, dipalmitoylphosphatidylglycerol, dipalmitoylphosphatidylserine, distearoylphosphatidic acid, distearoylphosphatidylglycerol, distearoylphosphatidylserine and mixtures thereof.

### Claim 8 (depends on 1)

The ultrasound contrast agent of claim 1, wherein the saturated phospholipid comprises distearoylphosphatidylcholine (DSPC) and dipalmitoylphosphatidylglycerol (DPPG).

### Claim 9 (depends on 1, 6, 8)

The ultrasound contrast agent of any one of claims 1, 6 or 8 wherein the hydrophilic stabilizer comprises PEG 4000.

### Claim 10 (depends on 1)

The ultrasound contrast agent of claim 1, wherein the saturated phospholipid comprises distearoylphosphatidylcholine (DSPC) and dipalmitoylphosphatidylglycerol (DPPG), the fatty acid comprises palmitic acid in an amount between 10 and 15% by weight of the amount of the saturated phospholipid, and the hydrophilic stabilizer comprises PEG 4000.

### Claim 11

A method of imaging a region of a body comprising:
(a) administering to the body an aqueous suspension of gas filled microbubbles comprising a saturated phospholipid, a fatty acid, a hydrophilic stabilizer, and SF6, wherein the amount of the saturated phospholipid in the suspension is less than 0.01% by weight; and
(b) imaging the body.

### Claim 12 (depends on 11)

The method of imaging of claim 11, wherein the fatty acid is present in an amount between 1% and 50% by weight of the amount of the saturated phospholipid.

### Claim 13 (depends on 11)

The method of imaging of claim 11, wherein the fatty acid is present in an amount between 5% and 25% by weight of the amount of the saturated phospholipid.

### Claim 14 (depends on 11)

The method of imaging of claim 11, wherein the fatty acid is present in an amount between 10% and 15% by weight of the amount of the saturated phospholipid.

### Claim 15 (depends on 11)

The method of imaging of claim 11, wherein the fatty acid is a C12-C24 straight chain saturated fatty acid selected from the group consisting of lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid and mixtures thereof.

### Claim 16 (depends on 11)

The method of imaging of claim 11, wherein the fatty acid comprises palmitic acid in an amount between 10% and 15% by weight of the amount of the saturated phospholipid.

### Claim 17 (depends on 11)

The method of imaging of claim 11, wherein the saturated phospholipid is selected from the group consisting of dimyristoylphosphatidic acid, dimyristoylphosphatidylglycerol, dimyristoylphosphatidylserine, dipalmitoylphosphatidic acid, dipalmitoylphosphatidylglycerol, dipalmitoylphosphatidylserine, distearoylphosphatidic acid, distearoylphosphatidylglycerol, distearoylphosphatidylserine and mixtures thereof.

### Claim 18 (depends on 11)

The method of imaging of claim 11, wherein the saturated phospholipid comprises distearoylphosphatidylcholine (DSPC) and dipalmitoylphosphatidylglycerol (DPPG).

### Claim 19 (depends on 11, 16, 18)

The method of imaging of any one of claims 11, 16 or 18, wherein the hydrophilic stabilizer comprises PEG 4000.

### Claim 20 (depends on 11)

The method of imaging of claim 11, wherein the saturated phospholipid comprises distearoylphosphatidylcholine (DSPC) and dipalrnitoylphosphatidylglycerol (DPPG), the fatty acid comprises palmitic acid in an amount between 10% and 15% by weight of the amount of the saturated phospholipid, and the hydrophilic stabilizer comprises PEG 4000.

### Claim 21 (depends on 11)

The method of imaging of claim 11, wherein the body is a vertebrate and the suspension is administered to the vasculature or body cavity of the vertebrate.

### Claim 22

A dry formulation of an ultrasound contrast agent comprising a saturated phospholipid, a fatty acid, and a hydrophilic stabilizer, wherein upon dissolution in an aqueous carrier liquid, the dry formulation will form a suspension of microbubbles comprising SF6 in which the amount of saturated phospholipid in the suspension is less than about 0.01% by weight.

### Claim 23 (depends on 22)

The dry formulation of claim 22, wherein the fatty acid is present in an amount of between 1% and 50% by weight of the amount of the saturated phospholipid.

### Claim 24 (depends on 22)

The dry formulation of claim 22, wherein the fatty acid is present in an amount of between 5% and 25% by weight of the amount of the saturated phospholipid.

### Claim 25 (depends on 22)

The dry formulation of claim 22, wherein the fatty acid is present in an amount of between 10% and 15% by weight of the amount of the saturated phospholipid.

### Claim 26 (depends on 22)

The dry formulation of claim 22, wherein the fatty acid is a C12-C24 straight chain saturated fatty acid selected from the group consisting of lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid and mixtures thereof.

### Claim 27 (depends on 22)

The dry formulation of claim 22, wherein the fatty acid comprises palmitic acid in an amount of between 10% and 15% by weight of the amount of the saturated phospholipid.

### Claim 28 (depends on 22)

The dry formulation of claim 22, wherein the saturated phospholipid is selected from the group consisting of dimyristoylphosphatidic acid, dimyristoylphosphatidylglycerol, dimyristoylphosphatidylserine, dipalmitoylphosphatidic acid, dipalmitoylphosphatidylglycerol, dipalmitoylphosphatidylserine, distearoylphosphatidic acid, distearoylphosphatidylglycerol, distearoylphosphatidylserine and mixtures thereof.

### Claim 29 (depends on 22)

The dry formulation of claim 22, wherein the saturated phospholipid comprises distearoylphosphatidylcholine (DSPC) and dipalmitoylphosphatidylglycerol (DPPG).

### Claim 30 (depends on 22, 27, 29)

The dry formulation of any one of claims 22, 27 or 29, wherein the hydrophilic stabilizer comprises PEG 4000.

### Claim 31 (depends on 22)

The dry formulation of claim 22, wherein the saturated phospholipid comprises distearoylphosphatidylcholine (DSPC) and dipalmitoylphosphatidylglycerol (DPPG), the fatty acid comprises palmitic acid in an amount of between 10% and 15% by weight of the amount of the saturated phospholipid, and the hydrophilic stabilizer comprises PEG 4000.

### Claim 32 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 31)

A method of using the dry formulation of any one of claims 22 to 29 or 31 for the preparation of an ultrasound contrast agent comprising forming a suspension of gas filled microbubbles with the dry formulation.

### Claim 33 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 31)

A method of preparing an ultrasound contrast agent comprising reconstituting the dry formulation of any one of claims 22 to 29 or 31 in an aqueous carrier liquid to form a suspension of gas filled microbubbles.

### Claim 34 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 31)

A method of imaging a region of a body comprising:
(a) reconstituting the dry formulation of any one of claims 22 to 29 or 31 in an aqueous carrier liquid to form a suspension of gas filled microbubbles;
(b) administering the suspension of gas filled microbubbles to the body; and
(c) imaging the body.

### Claim 35

A method of preparing a contrast agent comprising an aqueous suspension of gas filled microbubbles comprising SF6 and saturated phospholipid, wherein the amount of saturated phospholipid in the suspension is less than about 0.01% by weight, the method comprising:
(a) dissolving at least one saturated phospholipid, a fatty acid, and a hydrophilic stabilizer in an organic solvent to form a solution;
(b) freeze drying or spray drying the solution to form a dried powder;
(c) contacting the dried powder with SF6; and
(d) mixing the freeze dried or spray dried powder with an aqueous carrier phase.

### Claim 36

A method of preparing a dry formulation of an ultrasound contrast agent, wherein upon dissolution in an aqueous carrier liquid, the dry formulation will form a suspension of microbubbles comprising SF6 and saturated phospholipid, wherein the amount of the saturated phospholipid in the suspension is less than about 0.01% by weight, the method comprising:
(a) dissolving at least one saturated phospholipid, a fatty acid, and a hydrophilic stabilizer in an organic solvent to form a solution;
(b) freeze drying or spray drying the solution to form a dried powder; and
(c) contacting the dried powder with SF6.

### Claim 37

A method of preparing a dry formulation of an ultrasound contrast agent, wherein upon dissolution in an aqueous carrier liquid, the dry formulation will form a suspension of microbubbles comprising SF6 and saturated phospholipid, wherein the amount of the saturated phospholipid in the suspension is less than about 0.01% by weight, the method comprising:
(a) dissolving at least one saturated phospholipid and a hydrophilic stabilizer in an organic solvent to form a solution;
(b) freeze drying or spray drying the solution to form a dried powder;
(c) mixing the dried powder with a fatty acid to form a mixture; and
(d) contacting the mixture with SF6.

### Claim 38

An ultrasound contrast agent comprising an aqueous suspension of gas filled microbubbles comprising a saturated phospholipid, a preserving agent, SF6, and a hydrophilic stabilizer, wherein the amount of saturated phospholipid in the suspension is less than about 0.01% by weight, and the preserving agent comprises a fatty acid.

### Claim 39 (depends on 38)

The ultrasound contrast agent of claim 38, wherein the preserving agent is present in an amount between 1% and 50% by weight of the amount of the saturated phospholipid.

### Claim 40 (depends on 38)

The ultrasound contrast agent of claim 38, wherein the preserving agent is present in an amount between 5% and 25% by weight of the amount of the saturated phospholipid.

### Claim 41 (depends on 38)

The ultrasound contrast agent of claim 38, wherein the preserving agent is present in an amount between 10% and 15% by weight of the amount of the saturated phospholipid.

### Claim 42 (depends on 38)

The ultrasound contrast agent of claim 38, wherein the preserving agent is a C12-C24 straight chain saturated fatty acid selected from the group consisting of lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid and mixtures thereof.

### Claim 43 (depends on 38)

The ultrasound contrast agent of claim 38, wherein the preserving agent comprises palmitic acid in an amount between 10% and 15% by weight of the amount of the saturated phospholipid.

### Claim 44 (depends on 38)

The ultrasound contrast agent of claim 38, wherein the saturated phospholipid is selected from the group consisting of dimyristoylphosphatidic acid, dimyristoylphosphatidylglycerol, dimyristoylphosphatidylserine, dipalmitoylphosphatidic acid, dipalmitoylphosphatidylglycerol, dipalmitoylphosphatidylserine, distearoylphosphatidic acid, distearoylphosphatidylglycerol, distearoylphosphatidylserine and mixtures thereof.

### Claim 45 (depends on 38)

The ultrasound contrast agent of claim 38, wherein the saturated phospholipid comprises distearoylphosphatidylcholine (DSPC) and dipalmitoylphosphatidylglycerol (DPPG).

### Claim 46 (depends on 38, 43, 45)

The ultrasound contrast agent of any one of claims 38, 43 or 45, wherein the hydrophilic stabilizer comprises PEG 4000.

### Claim 47 (depends on 38)

The ultrasound contrast agent of claim 38, wherein the saturated phospholipid comprises distearoylphosphatidylcholine (DSPC) and dipalmitoylphosphatidylglycerol (DPPG), the preserving agent comprises palmitic in an amount between 10% and 15% by weight of the amount of the saturated phospholipid, and the hydrophilic stabilizer comprises PEG 4000.

### Claim 48

A dry formulation of an ultrasound contrast agent comprising a saturated phospholipid, a preserving agent, and a hydrophilic stabilizer, wherein the preserving agent comprises a fatty acid, and upon dissolution in an aqueous carrier liquid, the dry formulation will form a suspension of microbubbles comprising SF6 in which the amount of saturated phospholipid in the suspension is less than about 0.01% by weight.

### Claim 49 (depends on 48)

The dry formulation of claim 48, wherein the preserving agent is present in an amount between 1% and 50% by weight of the amount of the saturated phospholipid.

### Claim 50 (depends on 48)

The dry formulation of claim 48, wherein the preserving agent is present in an amount between 5% and 25% by weight of the amount of the saturated phospholipid.

### Claim 51 (depends on 48)

The dry formulation of claim 48, wherein the preserving agent is present in an amount between 10% and 15% by weight of the amount of the saturated saturated phospholipid.

### Claim 52 (depends on 48)

The dry formulation of claim 48, wherein the preserving agent is a C12-C24 straight chain saturated fatty acid selected from the group consisting of lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid and mixtures thereof.

### Claim 53 (depends on 48)

The dry formulation of claim 48, wherein the preserving agent comprises palmitic acid in an amount between 10% and 15% by weight of the amount of the saturated phospholipid.

### Claim 54 (depends on 48)

The dry formulation of claim 48, wherein the saturated phospholipid is selected from the group consisting of dimyristoylphosphatidic acid, dimyristoylphosphatidylglycerol, dimyristoylphosphatidylserine, dipalmitoylphosphatidic acid, dipalrnitoylphosphatidylglycerol, dipalmitoylphosphatidylserine, distearoylphosphatidic acid, distearoylphosphatidylglycerol, distearoylphosphatidylserine and mixtures thereof.

### Claim 55 (depends on 48)

The dry formulation of claim 48, wherein the saturated phospholipid comprises distearoylphosphatidylcholine (DSPC) and dipalmitoylphosphatidylglycerol (DPPG).

### Claim 56 (depends on 48, 53, 55)

The dry formulation of any one of claims 48, 53 or 55, wherein the hydrophilic stabilizer comprises PEG 4000.

### Claim 57 (depends on 48)

The dry formulation of claim 48, wherein the saturated phospholipid comprises distearoylphosphatidylcholine (DSPC) and dipalmitoylphosphatidylglycerol (DPPG), the preserving agent comprises palmitic acid in an amount between 10% and 15% by weight of the amount of the saturated phospholipid, and the hydrophilic stabilizer comprises PEG 4000.

### Claim 58 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 57)

A method of using the dry formulation of any one of claims 48 to 55 or 57 for the preparation of an ultrasound contrast agent comprising forming a suspension of gas filled microbubbles from the dry formulation.

### Claim 59 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 57)

A method of preparing an ultrasound contrast agent comprising reconstituting the dry formulation of any one of claims 48 to 55 or 57 in an aqueous carrier liquid to form a suspension of gas filled microbubbles.

### Claim 60 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 57)

A method of imaging a region of a body comprising:
(a) reconstituting the dry formulation of any one of claims 48 to 55 or 57 in an aqueous carrier liquid to form a suspension of gas filled microbubbles;
(b) administering the suspension of gas filled microbubbles to the body; and
(c) imaging the body.
